Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders
Completed
Conditions studied: Polycythemia Vera, Essential Thrombocytosis, Idiopathic Myelofibrosis, Neutrophils, Chronic Myeloproliferative Disorders
In brief
The three main chronic myeloproliferative disorders are polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF). These are clonal neoplastic diseases characterized by proliferation of one or more hematopoietic lineages. Recently a mutation of the Janus Kinase 2 (JAK2) gene that leads to the substitution of phenylalanine for valine at position 617 of the JAK2 protein, JAK2 V617F, has been found in 76% to 97% of patients with PV, 29% to 57% of patients with ET and 50% of patients with IMF. This mutation confers constitutive activity on to the JAK2 protein and appears to play an important role in the pathobiology of these conditions. However, not all patients with myeloproliferative disorders have this mutation and it may not be the primary cause of these diseases. The primary goal of this prospective natural history study is to investigate the molecular basis of these diseases in groups of patients who have JAK2 V617F and in those who do not. A second goal is to identify biomarkers for PV and the other myeloproliferative disorders that are easier to measure than JAK2 V617F. Approximately, 150 patients with myeloproliferative disorders will be studied over 3 years. The studies will involve the collection of 40 mL to 50 mL of peripheral blood from each subject. The blood will be used to assess neutrophil gene and protein expression, gene polymorphisms, and plasma protein levels.
Key facts
- Study ID
- NCT00433862
- Run by
- National Institutes of Health Clinical Center (CC)
- People needed
- 8
- Starts
- 2007-02-06
- Expected to finish
- 2010-05-19
- Last updated by the study team
- 2017-07-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may not qualify if…
- Subjects will be excluded if they have any of the following conditions:
- Increased blood counts due to a disease other than chronic myeloproliferation.
- Know history of anemia (hematocrit less than 12.0 mg/dL).
- Pregnancy.
- Infection with HIV, hepatitis B, or hepatitis C.
Where it is running
- VA Medical Center, Washington D.C. — Washington D.C., District of Columbia, United States
- National Institutes of Health Clinical Center, 9000 Rockville Pike — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.